Brief: Committee For Medicinal Products Has Adopted Negative Opinion On BioArctic's Lecanemab For EU
July 26 (Reuters) - BioArctic AB BIOAb.ST :
* CHMP HAS ADOPTED A NEGATIVE OPINION ON LECANEMAB FOR THE
EU
* IS CURRENTLY CONSULTING EISAI REGARDING FORTHCOMING
ACTIONS
* FURTHER UPDATE WILL BE COMMUNICATED LATER TODAY
* BIOARCTIC HAS RIGHT TO COMMERCIALIZE LECANEMAB IN NORDIC
REGION
Source text for Eikon: ID:nWkr48cMxW
Further company coverage: BIOAb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million